Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19

Luna Acharya; Alpana Garg; Manoj Rai; Rupesh Kshetri; Udhayvir S. Grewal; Prajwal Dhakal

doi:10.1177/10815589231191811

Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19

Luna Acharya, Alpana Garg, Manoj Rai, Rupesh Kshetri, Udhayvir S. Grewal, Prajwal Dhakal

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

Abstract

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults with a poor prognosis with relapsed or refractory (R/R) B-cell lineage ALL (B-ALL). Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown excellent response rates in RR B-ALL, but most patients relapse due to poor persistence of CAR T-cell therapy or other tumor-associated escape mechanisms. In addition, anti-CD19 CAR T-cell therapy causes several serious side effects such as cytokine release syndrome and neurotoxicity. In this review, we will discuss novel CAR targets, CAR constructs, and various strategies to boost CARs for the treatment of RR B-ALL. In addition, we discuss a few novel strategies developed to reduce the side effects of CAR.

Original language	English (US)
Pages (from-to)	32-46
Number of pages	15
Journal	Journal of Investigative Medicine
Volume	72
Issue number	1
DOIs	https://doi.org/10.1177/10815589231191811
State	Published - Jan 2024

Keywords

Oxidation–reduction
free radicals

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1177/10815589231191811

Cite this

@article{7e7ba48d4ce041318fb6be0215e700f1,

title = "Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19",

abstract = "Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults with a poor prognosis with relapsed or refractory (R/R) B-cell lineage ALL (B-ALL). Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown excellent response rates in RR B-ALL, but most patients relapse due to poor persistence of CAR T-cell therapy or other tumor-associated escape mechanisms. In addition, anti-CD19 CAR T-cell therapy causes several serious side effects such as cytokine release syndrome and neurotoxicity. In this review, we will discuss novel CAR targets, CAR constructs, and various strategies to boost CARs for the treatment of RR B-ALL. In addition, we discuss a few novel strategies developed to reduce the side effects of CAR.",

keywords = "Oxidation–reduction, free radicals",

author = "Luna Acharya and Alpana Garg and Manoj Rai and Rupesh Kshetri and Grewal, {Udhayvir S.} and Prajwal Dhakal",

note = "Publisher Copyright: {\textcopyright} 2023 American Federation for Medical Research.",

year = "2024",

month = jan,

doi = "10.1177/10815589231191811",

language = "English (US)",

volume = "72",

pages = "32--46",

journal = "Journal of Investigative Medicine",

issn = "1081-5589",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia

T2 - Moving beyond CD19

AU - Acharya, Luna

AU - Garg, Alpana

AU - Rai, Manoj

AU - Kshetri, Rupesh

AU - Grewal, Udhayvir S.

AU - Dhakal, Prajwal

PY - 2024/1

Y1 - 2024/1

N2 - Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults with a poor prognosis with relapsed or refractory (R/R) B-cell lineage ALL (B-ALL). Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown excellent response rates in RR B-ALL, but most patients relapse due to poor persistence of CAR T-cell therapy or other tumor-associated escape mechanisms. In addition, anti-CD19 CAR T-cell therapy causes several serious side effects such as cytokine release syndrome and neurotoxicity. In this review, we will discuss novel CAR targets, CAR constructs, and various strategies to boost CARs for the treatment of RR B-ALL. In addition, we discuss a few novel strategies developed to reduce the side effects of CAR.

AB - Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults with a poor prognosis with relapsed or refractory (R/R) B-cell lineage ALL (B-ALL). Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown excellent response rates in RR B-ALL, but most patients relapse due to poor persistence of CAR T-cell therapy or other tumor-associated escape mechanisms. In addition, anti-CD19 CAR T-cell therapy causes several serious side effects such as cytokine release syndrome and neurotoxicity. In this review, we will discuss novel CAR targets, CAR constructs, and various strategies to boost CARs for the treatment of RR B-ALL. In addition, we discuss a few novel strategies developed to reduce the side effects of CAR.

KW - Oxidation–reduction

KW - free radicals

UR - http://www.scopus.com/inward/record.url?scp=85179839831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85179839831&partnerID=8YFLogxK

U2 - 10.1177/10815589231191811

DO - 10.1177/10815589231191811

M3 - Review article

C2 - 37497999

AN - SCOPUS:85179839831

SN - 1081-5589

VL - 72

SP - 32

EP - 46

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

IS - 1

ER -

Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this